The YCC Administration provides infrastructure to promote cancer research activities of its 260 members, with a particular emphasis on facilitating transdisciplinary and translational research. The Administration supports the Director, Senior Leaders, Program Leaders, Shared Resources Directors and YCC Members in carrying out the YCC mission through effective management, centralized resources, and strategic planning. YCC Administrative responsibilities: ? Communicate between and among Center Director, Deputy, Associate and Assistant Directors,, Program Leaders, Shared Resource Directors and stakeholders within and outside the Institution; ? Develop and implement the YCC strategic plan in concert with the Center's leadership and integrate recommendations from standing and ad hoc advisory boards; ? Develop and coordinate research administration activities to support planning and evaluation, integrate and promote the collaborative, transdisciplinary and translational research activities of the YCC; ? Provide financial management of all YCC and CCSG funds and accounts;maintain fiduciary responsibility including preparing and maintaining annual operating,, capital and Shared Resource budgets;intra- and extramural research fund management;tracking Shared Resource usage;preparing grants, contracts and other financial reports; * Provide personnel and human resource services in support of YCC leadership and membership; * Manage Shared-Resources and provide financial oversight, data on usage patterns, and determine chargeback rate; * Manage YCC facilities, space, and equipment; * Manage and coordinate funding opportunities including intramural pilot project programs and other research project post award management; * Support and coordinate YCC membership application and review processes; * Manage and respond to research information technology and informatics needs; * Coordinate YCC committees;management of human resources, development, marketing, public affairs, and education programs.

Public Health Relevance

The administration is a key component of the YCC. A highly effective administration is of paramount importance for the YCC and its members to achieve their missions. The administration's chief priority is to ensure the effective execution of business, administrative, and financial operations such that the research activities of YCC members can flourish.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
New Haven
United States
Zip Code
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications